Login Register Cart 0
Generic placeholder image

Current Pharmacogenomics and Personalized Medicine

Editor-in-Chief

ISSN (Print): 1875-6921
ISSN (Online): 1875-6913

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Evaluation of BRAF Mutations in Patients with Colorectal Cancer in the East of Iran

Author(s): Elham Serki, Atena Mansouri, Mohammad Malekaneh and Mohsen Naseri*

Volume 20, Issue 2, 2023

Published on: 12 July, 2023

Page: [87 - 91] Pages: 5

DOI: 10.2174/1875692120666230602115139

Price: $65

Abstract

Background: Several genetic alterations in cell growth regulatory genes, such as BRAF, are associated with colorectal cancer. Due to the introduction of biological agents designed to treat cancer, diagnostic tests using nucleic acids extracted from formalin-fixed and paraffin-embedded tissues are becoming more common.

Objective: This study aimed to determine the incidence of BRAF mutations in colorectal cancer patients.

Materials and Methods: 50 paraffin-embedded cancer specimens were obtained from Imam Reza Hospital of Birjand in Iran. PCR was used to amplify and sequence the BRAF gene exon 15, which was extracted from paraffin-embedded tissue using an improved technique.

Results: 2/43 (4%) of patients with colorectal cancer exhibited the BEAF V600E mutation. Most of the mutations occurred in patients over 50 years of age.

Conclusion: To understand how genetics and environment interact to influence the low incidence of BRAF mutations in the east of Iran, further research is needed to determine what is driving this low incidence of BRAF mutations and what factors contribute to it.

Keywords: Colorectal cancer, BRAF mutation, PCR, gene, DNA, cancer.

« Previous
Graphical Abstract

[1]
Sharma SG, and M.L. Gulley,. BRAF mutation testing in colorectal cancer. Archives of pathology & laboratory medicine, 2010; 134(8): 1225-8.
[2]
Naghibalhossaini F, et al. High frequency of genes’ promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients. Pathology & Oncology Research 2011; 17(4): 819-25.
[3]
Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA:a cancer Journal for clinicians 2018; 68(6): 394-424.
[4]
Gómez-España, M., et al., SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer. (2018) Clinical and Translational Oncology 2019 21(1): 46-54.
[5]
Hoeflich KP, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer research 2006; 66(2): 999-1006.
[6]
Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New England Journal of Medicine 2010; 363(9): 809-19.
[7]
Kopetz S, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. in ASCO Annual Meeting Proceedings 2010.
[8]
Puzanov I, P Burnett and KT, Flaherty . Biological challenges of BRAF inhibitor therapy. Molecular oncology 2011; 5(2): 116-23.
[9]
Bardelli A and S, Siena . Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. Journal of clinical oncology 2010; 28(7): 1254-61.
[10]
Lee S, et al. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Archiv 2012; 460(2): 141-9.
[11]
Didelot A, et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Experimental and molecular pathology 2012; 92(3): 275-80.
[12]
Javadi F, Geramizadeh B, Mirzai M. BRAFGene Mutation Analysis in Colorectal Cancer in South of Iran. Ann Colorectal Res 2014; 2(2): e19917.
[13]
Naseri M, et al. Frequency of K-RAS and N-RAS Gene Mutations in Colorectal Cancers in Southeastern Iran. Asian Pacific Journal of Cancer Prevention 2016; 17(9): 4511-5.
[14]
Dolatkhah R, et al. Colorectal cancer in Iran: molecular epidemiology and screening strategies. Journal of cancer epidemiology 2015.
[15]
Rajagopalan H, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418(6901): 934-4.
[16]
Yuen ST, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer research 2002; 62(22): 6451-5.
[17]
Fransén K, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004; 25(4): 527-33.
[18]
Ranjbari N, et al. BRAF mutations in Iranian patients with papillary thyroid carcinoma. Asian Pacific Journal of Cancer Prevention 2013; 14(4): 2521-3.
[19]
Mohammadi-Asl J, et al. Prevalence of BRAF V600E Mutation in Iranian Patients with Papillary Thyroid Carcinoma: A Single-Center Study. Journal of Applied Sciences 2009; 9(19)
[20]
Siraj AK, et al. A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Molecular cancer 2014; 13(1): 1.
[21]
Kadowaki S, et al. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World journal of gastroenterology. WJG 2015; 21(4): 1275.
[22]
Sun T, et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut. 2012; gutjnl-2012: p. 302423.
[23]
Brim H, et al. Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer 2008; 7(68): 10-1186.

Rights & Permissions Print Cite
Article Metrics
15
2
© 2024 Bentham Science Publishers | Privacy Policy